Breast Cancer

Do comorbid diagnoses affect breast cancer screening rates? The authors of this study present their findings.

Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.

The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.

Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States.

Abemaciclib plus nonsteroidal aromatase inhibitors were shown to be a successful initial treatment in a Japanese subpopulation, with a tolerable safety profile, consistent with findings in the whole population in treating patients with HR-positive, HER2-negative advanced breast cancer.

The therapeutic advantage of alpelisib over fulvestrant in the treatment of patients with HR-positive, HER2-negative breast cancer and other malignancies is further enhanced by a matched/weighted analysis comparing BYLieve with the real-world scenario.

Endocrine therapy used in combination with CDK4/6 inhibitors, in particular, have transformed the metastatic breast cancer landscape, promisingly improving progression-free survival and overall survival among patients with HR-positive, HER2-negative metastatic breast cancer.

Neoadjuvant chemotherapy is becoming more popular for patients with locally advanced breast cancer. Downstaging may result in a smaller surgical extent or a higher breast conservation rate, and a better cosmetic outcome. Chemotherapy, on the other hand, has both short- and long-term complications.

Treatment with ICIs in metastatic TNBC has shown encouraging results. Immunotherapy has shifted the paradigm of cancer treatment and opened new research opportunities. TNBC is characterized by immunologic activation while being the most common subtype of breast cancer.